# 2025-05591: DEA Yanks Registration from Opioid-Rule-Breaking Pharmacy

2025-05591, Prescript Pharmaceuticals; Decision and Order, is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-04-02, effective 2025-05-02; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-05591
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-05591
- Title: Prescript Pharmaceuticals; Decision and Order
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 14476
- Published: 2025-04-02
- Effective: 2025-05-02
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

DEA Yanks Registration from Opioid-Rule-Breaking Pharmacy

## Summary

Prescript Pharmaceuticals got their DEA registration suspended and revoked because they ordered powerful opioids without proper approval between 2020 and 2023. This affects the company directly and means they can’t legally handle these drugs anymore, protecting public health. The decision is final and signals serious consequences for companies that don’t follow drug safety rules.

## Effects PRIA read

- DEA Registration Revoked for Prescript: cost, high. The DEA revoked Prescript Pharmaceuticals' Certificate of Registration No. RP0177798, effective May 2, 2025. The agency found that Prescript ordered Schedule II opioids (hydrocodone and oxycodone) from 2020 through 2023 without requesting or receiving procurement quota as required by 21 CFR 1303.12…
- Pending Renewal and New Applications Denied: cost, high. The Order denies any pending applications of Prescript Pharmaceuticals to renew or modify Certificate No. RP0177798 and denies any other pending application for additional registration in California. That denial takes effect with the Order effective May 2, 2025.
- DEA May Adjudicate Expired Registrations: cost, medium. The Agency states it has jurisdiction to adjudicate a registrant's conduct to finality even if the registrant's DEA registration has expired. The Order explains the Agency's jurisdiction is over the registrant (not the registration) and that final orders may be issued after a registration expires.
- Final Order Clarifies Seized Inventory Disposition: cost, medium. The Order notes that controlled substances seized from Prescript when the OSC/ISO was served remain outstanding and that issuing a final order will clarify the disposition of those seized assets. The record shows Prescript's registration expired on March 31, 2024, but the disposition of seized cont…
- Order Sends Strong Deterrent Message: cost, low. The Agency explains that revocation is intended to serve both specific and general deterrence, warning other registrants that repeatedly ignoring quota rules can lead to revocation. The decision emphasizes that allowing Prescript to retain registration would signal that registrants may choose which…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-05591 on federalregister.gov](https://www.federalregister.gov/documents/2025/04/02/2025-05591/prescript-pharmaceuticals-decision-and-order)
- [2025-05591 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-04-02/pdf/2025-05591.pdf)

## Related
- [Previous: 2025-05589, Self-Regulatory Organizations; Cboe BZX Exchange, Inc.; Notice of Filing of a P…](https://policyrisk.com/federal-register/2025-05589)
- [Next: 2025-05594, Notice of Inventory Completion: Peabody Museum of Archaeology and Ethnology, Ha…](https://policyrisk.com/federal-register/2025-05594)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-05591 (as of 2026-06-08).
